Company intelligence / Profile preview
Immune Pharmaceuticals Inc.
Fort Lee, New Jersey, United Statesimmunepharma.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 2
01
Overview
The company developed various therapeutic agents for immunologic and inflammatory diseases. Their lead product was bertilimumab, a human antibody in Phase II clinical trials for bullous pemphigoid and ulcerative colitis.
- Therapeutic areas
- EndocrinologyHematologyDermatologyGastroenterologyNeurology
- Modalities
- Monoclonal antibodiesNano-encapsulated formulationsTopical analgesics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Vector Therapeutics (Ceplene rights)WuXi Biologics
Beyond the preview
Go deeper on Immune Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immune Pharmaceuticals Inc..